SCHEMBL6489116

SCHEMBL6489116

Cc1cc2cc(NC(=O)C3CC3)ccc2n1C(=O)c1c(F)cccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.44
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ABL1 P00519 2/20 0.41
TP53 P04637 1/20 0.41
MGLL Q99685 1/20 0.40
F2 P00734 1/20 0.40
ELANE P08246 1/20 0.40
CTRB1 P17538 1/20 0.40
JAK1 P23458 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480722 0.96 NPSR1 (0.49) HSD17B10NPSR1ELANEMAOAMAOB
SCHEMBL6480771 0.96 NPSR1 (0.46) HSD17B10MAPTNPSR1ABL1MAOA
SCHEMBL6490688 0.94 MGLL (0.44) HSD17B10MAPTKMT2AMEN1MGLL
SCHEMBL6480917 0.91 RORC (0.46) HSD17B10MAPTKMT2AMEN1USP2
SCHEMBL6492402 0.90 NPSR1 (0.46) NPSR1MGLLJAK1MAOAMAOB
SCHEMBL6489974 0.90 JAK2 (0.43) HSD17B10MAPTKMT2ANPSR1MGLL
SCHEMBL6492666 0.89 NPSR1 (0.45) NPSR1MGLLMAOAMAOBUSP2
SCHEMBL6489189 0.89 HSD17B10 (0.46) HSD17B10MAPTKMT2AMEN1NPSR1
SCHEMBL6487994 0.88 MEN1 (0.46) MAPTKMT2AMEN1NPSR1MGLL
SCHEMBL6480480 0.88 RORC (0.43) HSD17B10MAPTKMT2AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 HSD17B10 980/4885MAPT 3587/4885KMT2A 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.